Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
Palma Manduzio Department of Haematology and Oncology, Haematology With BMT, IRCCS, Casa Sollievo della Sofferenza, Foggia, Italy Abstract: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm classified according to the 2016 revision of World Health Organization Classification of Tumors a...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-02-01
|
| Series: | Therapeutics and Clinical Risk Management |
| Subjects: | |
| Online Access: | https://www.dovepress.com/ruxolitinib-in-myelofibrosis-to-be-or-not-to--be-an-immune-disruptor-peer-reviewed-article-TCRM |